Skip to main content
NYSE:HQL

Tekla Life Sciences Investors Stock Forecast, Price & News

$19.71
+0.30 (+1.55 %)
(As of 05/17/2021 12:00 AM ET)
Add
Compare
Today's Range
$19.37
$19.73
50-Day Range
$19.14
$20.79
52-Week Range
$16.60
$22.32
Volume61,758 shs
Average Volume84,339 shs
Market Capitalization$478.54 million
P/E RatioN/A
Dividend Yield8.14%
Beta1.09
30 days | 90 days | 365 days | Advanced Chart
Receive HQL News and Ratings via Email

Sign-up to receive the latest news and ratings for Tekla Life Sciences Investors and its competitors with MarketBeat's FREE daily newsletter.


About Tekla Life Sciences Investors

Tekla Life Sciences Investors is a closed-ended equity mutual fund launched and managed by Tekla Capital Management LLC. The fund invests in public equity markets across the globe. It seeks to invest in stocks of companies operating in the life sciences sector, including the biotechnology, pharmaceutical, diagnostics, managed healthcare, medical equipment, hospitals, healthcare information technology and services, devices and supplies industries, and in agriculture and environmental management industries. The fund primarily invests in growth stocks of small cap companies. It employs fundamental analysis with a focus on factors such as market position for services or products, experience of business management, technological expertise, and the ability either to generate funds internally to finance growth or to secure outside sources of capital to create its portfolio. The fund benchmarks the performance of its portfolio against the NASDAQ Biotech Index and the S&P 500 Index. It was formerly known as H&Q Life Sciences Investors fund. Tekla Life Sciences Investors was formed on February 20, 1992 and is domiciled in the United States.

Headlines

Tekla Life Sciences Investors (NYSE:HQL) Short Interest Update
Tekla Life Sciences Investors (NYSE:HQL) Short Interest Update
April 29, 2021 |  americanbankingnews.com
Tekla Life Sciences Investors Declares Cash Distribution
Tekla Life Sciences Investors Declares Cash Distribution
December 21, 2020 |  finance.yahoo.com
Understanding Tekla Life Sciencess Ex-Dividend Date
Understanding Tekla Life Sciences's Ex-Dividend Date
November 24, 2020 |  benzinga.com
Tekla Life Sciences Investors Declares Distribution
Tekla Life Sciences Investors Declares Distribution
November 16, 2020 |  finance.yahoo.com
HQH: Deep Discount Leads To High Yield
HQH: Deep Discount Leads To High Yield
November 9, 2020 |  seekingalpha.com
HQL TeklaLife Sciences Investors Common Stock
HQL TeklaLife Sciences Investors Common Stock
May 15, 2020 |  www.nasdaq.com
Tekla Life Sciences declares $0.39 dividend
Tekla Life Sciences declares $0.39 dividend
February 18, 2020 |  seekingalpha.com
Tekla Life Sciences Investors Declares Stock Distribution
Tekla Life Sciences Investors Declares Stock Distribution
February 18, 2020 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry Investment offices, not elsewhere classified
Sub-IndustryN/A
SectorFinance
CUSIPN/A
Phone617-772-8500
EmployeesN/A
Year FoundedN/A

Sales & Book Value

Annual SalesN/A

Profitability

Debt

Price-To-Earnings

Miscellaneous

Market Cap$478.54 million
Next Earnings DateN/A
OptionableNot Optionable

MarketRank

Overall MarketRank

0.85 out of 5 stars

Finance Sector

1211th out of 1,930 stocks

Investment Offices, Not Elsewhere Classified Industry

63rd out of 172 stocks

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles











Tekla Life Sciences Investors (NYSE:HQL) Frequently Asked Questions

What stocks does MarketBeat like better than Tekla Life Sciences Investors?

Wall Street analysts have given Tekla Life Sciences Investors a "N/A" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Tekla Life Sciences Investors wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Tekla Life Sciences Investors?

Tekla Life Sciences Investors saw a drop in short interest during the month of April. As of April 15th, there was short interest totaling 48,300 shares, a drop of 60.5% from the March 31st total of 122,300 shares. Based on an average daily trading volume, of 86,900 shares, the short-interest ratio is currently 0.6 days.
View Tekla Life Sciences Investors' Short Interest
.

How has Tekla Life Sciences Investors' stock price been impacted by COVID-19?

Tekla Life Sciences Investors' stock was trading at $14.85 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, HQL shares have increased by 32.7% and is now trading at $19.71.
View which stocks have been most impacted by COVID-19
.

How often does Tekla Life Sciences Investors pay dividends? What is the dividend yield for Tekla Life Sciences Investors?

Tekla Life Sciences Investors declared a quarterly dividend on Wednesday, February 17th. Shareholders of record on Friday, February 26th will be paid a dividend of $0.43 per share on Wednesday, March 31st. This represents a $1.72 annualized dividend and a yield of 8.73%. The ex-dividend date of this dividend is Thursday, February 25th. This is an increase from Tekla Life Sciences Investors's previous quarterly dividend of $0.40.
View Tekla Life Sciences Investors' dividend history
.

Is Tekla Life Sciences Investors a good dividend stock?

Tekla Life Sciences Investors pays an annual dividend of $1.58 per share and currently has a dividend yield of 8.14%. HQL has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
View Tekla Life Sciences Investors' dividend history.

Who are Tekla Life Sciences Investors' key executives?

Tekla Life Sciences Investors' management team includes the following people:
  • Dr. Daniel R. Omstead M.S, Ph.D., Principal Exec. Officer, Pres and Trustee (Age 68)

Who are some of Tekla Life Sciences Investors' key competitors?

What other stocks do shareholders of Tekla Life Sciences Investors own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Tekla Life Sciences Investors investors own include NVIDIA (NVDA), Energy Transfer (ET), QUALCOMM (QCOM), AT&T (T), Enbridge (ENB), International Business Machines (IBM), Kinder Morgan (KMI), Main Street Capital (MAIN), Pfizer (PFE) and Weyerhaeuser (WY).

What is Tekla Life Sciences Investors' stock symbol?

Tekla Life Sciences Investors trades on the New York Stock Exchange (NYSE) under the ticker symbol "HQL."

Who are Tekla Life Sciences Investors' major shareholders?

Tekla Life Sciences Investors' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Advisors Asset Management Inc. (1.72%), Flagship Harbor Advisors LLC (1.33%), Cohen & Steers Inc. (0.68%), UBS Group AG (0.50%), Atlantic Union Bankshares Corp (0.41%) and Ameriprise Financial Inc. (0.38%).
View institutional ownership trends for Tekla Life Sciences Investors
.

Which major investors are selling Tekla Life Sciences Investors stock?

HQL stock was sold by a variety of institutional investors in the last quarter, including Cohen & Steers Inc., Usca Ria LLC, Stifel Financial Corp, Titus Wealth Management, Shepherd Kaplan Krochuk LLC, Guggenheim Capital LLC, Powell Investment Advisors LLC, and Eudaimonia Partners LLC.
View insider buying and selling activity for Tekla Life Sciences Investors
or view top insider-selling stocks.

Which major investors are buying Tekla Life Sciences Investors stock?

HQL stock was purchased by a variety of institutional investors in the last quarter, including Atlantic Union Bankshares Corp, Advisors Asset Management Inc., Hennion & Walsh Asset Management Inc., Flagship Harbor Advisors LLC, UBS Group AG, International Assets Investment Management LLC, Quad Cities Investment Group LLC, and Commonwealth Equity Services LLC.
View insider buying and selling activity for Tekla Life Sciences Investors
or or view top insider-buying stocks.

How do I buy shares of Tekla Life Sciences Investors?

Shares of HQL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Tekla Life Sciences Investors' stock price today?

One share of HQL stock can currently be purchased for approximately $19.71.

How much money does Tekla Life Sciences Investors make?

Tekla Life Sciences Investors has a market capitalization of $478.54 million.

What is Tekla Life Sciences Investors' official website?

The official website for Tekla Life Sciences Investors is www.teklacap.com.

Where are Tekla Life Sciences Investors' headquarters?

Tekla Life Sciences Investors is headquartered at 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109.

How can I contact Tekla Life Sciences Investors?

Tekla Life Sciences Investors' mailing address is 2 LIBERTY SQUARE 9TH FLOOR, BOSTON MA, 02109. The company can be reached via phone at 617-772-8500 or via email at [email protected]


This page was last updated on 5/18/2021 by MarketBeat.com Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.